Trial
DO-HEALTH
Research Observatory
Evidence Update
Current evidence
DO-HEALTH tested algal omega-3 1 g/day, vitamin D3 2000 IU/day and home strength exercise in a factorial trial of 2,157 older adults. The methylation analysis used 777 Swiss participants with paired samples, comparing algal omega-3 1 g/day with its placebo while accounting for the vitamin D and exercise assignments; exercise controls included flexibility activity. DO-HEALTH's selected methylation substudy found small omega-3-related changes in PhenoAge, GrimAge2 and DunedinPACE, not proof of clinical rejuvenation or lifespan gain.
What changed
The methylation analysis includes 777 people with paired samples from a 2,157-person parent trial, not 1,554 independent participants.
What did not change
Clock response does not establish lifespan extension or whole-body rejuvenation.
Why it matters
Adds a new response setting while preserving existing version and surrogate boundaries.
Main limitation
Multiplicity, subset selection and unvalidated surrogate interpretation. Clock months are not added life months; specific versions cannot be merged.
Next proof
Link biomarker changes to independently demonstrated clinical outcomes before surrogate promotion.
Summary
DO-HEALTH tested algal omega-3 1 g/day, vitamin D3 2000 IU/day and home strength exercise in a factorial trial of 2,157 older adults. The methylation analysis used 777 Swiss participants with paired samples, comparing algal omega-3 1 g/day with its placebo while accounting for the vitamin D and exercise assignments; exercise controls included flexibility activity. DO-HEALTH's selected methylation substudy found small omega-3-related changes in PhenoAge, GrimAge2 and DunedinPACE, not proof of clinical rejuvenation or lifespan gain.
Intelligence Take
Adds a new response setting while preserving existing version and surrogate boundaries.
Limitations
Multiplicity, subset selection and unvalidated surrogate interpretation. Clock months are not added life months; specific versions cannot be merged.